Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201809-05 Development of Selective Insulin Receptor Agonist Aptamer(Metabolic Disorders, Genetics) [2019-06-24]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

- Development of aptamer-based anti-diabetic therapeutics without inducing insulin-resistance

- Candidate substances for preclinical studies

Unmet Medical Need & Target Patients

- Patients in T1D and T2D necessary the basal insulin treatment constantly, and patients with severe insulin resistance necessary the ultra-high dose insulin treatment

- Most pressing unmet needs are the development of a breakthrough drug providing sustained improvement in glycemic control, addressing insulin resistance, and reducing b-cell dysfunction

- Reduction or management of side effects due to the long-term treatment of insulin including hypoglycemia, weight gain, and increase of CVD risk

Status

- Completion of lead optimization

- Completion of rodent PK profiling

- On-going of CMC studies and additional in vivo efficacy studies

 

Intellectual Property

Completion of PCT application of the optimized lead compound (2018)

Competitive Advantages

- Glucose lowering effect via the full activation of an insulin receptor

- Maintenance of insulin sensitivity and reducing insulin-induced insulin resistance via blocking the receptor internalization

- Reduction of weight gain and CVD risk due to side effects of insulin treatment (Highly selective binding to an insulin receptor à No off-target effect such as IGF1R binding and signaling)

- Reduction of hypoglycemia and stable pharmacokinetic properties

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code